China's NCI Approval Updates: Five Ingredients, Five Technical Paths

Publication date：2026-02-24

From February 6 to 24, 2026, 5 new cosmetic ingredients (NCIs) have completed notifications with China's National Medical Products Administration (NMPA).

Although the technical requirements have not yet been disclosed, their general categories can be inferred from the ingredient nomenclature. Judging from the names, they cover a plant extract, a fermentation-derived ingredient, a synthetic polymer, a nucleic acid–based derivative, and a bioactive peptide.

Dendrobium Huoshanense Stem Extract

Dendrobium huoshanense, also known as Mi Hu (米斛), is a Dendrobium species endemic to Huoshan County, Anhui Province, China. It is regarded as the most valuable species among Dendrobium used in traditional Chinese medicine. Owing to its distinctive therapeutic and health-promoting properties, it has been highly esteemed by physicians throughout history and classified as a top-grade medicinal herb. Dendrobium huoshanense is listed as a National Class I Endangered Medicinal Plant in China and is therefore often referred to as the "giant panda of medicinal plants."

Fermentation-derived Ingredient

Based on the ingredient name, Notification No. 20260028 appears to be a plant extract further processed through probiotic fermentation. Since 2021, the notifier, UNIASIA TECHNOLOGY, has completed the filing of four new cosmetic ingredients, all of which are fermentation-derived ingredients.

Founded in 2006, UNIASIA TECHNOLOGY is an integrated company engaged in R&D, manufacturing, sales, and services. Its brand portfolio includes MEIFUBAO, FRANIC, See Young, and SIGHTFUTURE, covering skincare, haircare, body care, and essential oils.

Functional Polymer

Notification No. 20260029 was filed by Guangzhou Muke Biotechnology Co., Ltd., a company founded in 2013 and involved in the R&D and commercialization of skincare and haircare products, including brands such as WIS and KONO.

Nucleic Acid Derivative

Notification No. 20260030 was filed by Fuaisha Biotechnology (Shaoxing) Co., Ltd., a company established in 2025 and wholly owned by Chengdu IncTAC Biotechnology Co., Ltd.

IncTAC is a biotechnology company engaged in the research and development of lncRNA-based therapeutics, with a focus on nucleic acid drugs targeting traditionally undruggable targets. Its core business is primarily oriented toward the healthcare and pharmaceutical sectors.

In May 2025, IncTAC joined the Bayer Co.Lab platform. This collaboration with a multinational pharmaceutical company may provide additional resources and industry connectivity to support the company's ongoing research in nucleic acid drug delivery technologies.

Bioactive Peptide

Notification No. 20260031 was filed by Nuoweitai (Kunming) Biotechnology Co., Ltd., a company established in 2023 and a subsidiary of Botanee Group. As of now, the company has filed three NCIs, with all notifications completed in 2026.